湿性年龄相关性黄斑变性和糖尿病性黄斑水肿治疗新药—Faricimab

New drug for wet age-related macular degeneration and diabeti edemaFaricimab

Faricimab是血管生成素-2(Ang-2)和抗血管内皮生长因子(VEGF)的双靶向抑制药。2022年1月,FDA批准faricimab注射剂通过玻璃体内注射使用治疗新生血管(湿性)年龄相关性黄斑变性(nAMD)和糖尿病性黄斑水肿(DME)。研究显示,faricimab的给药间隔可以最多延长到16周。最常见的药物不良反应为结膜出血。本文对faricimab的药理作用、药代动力学、临床评价、安全性及用法用量方面进行综述,旨在为临床合理用药提供参考。

Faricimab is a dual targeted inhibitor of angiogenin-2(Ang-2)and vascular endothelial growth factor(VEGF).In January 2022,faricimab injection was approved by FDA for use via intravitreal injection to treat neovascular(wet)age-related macular degeneration(nAMD)and diabetic macular edema(DME).It is reported that faricimab can be administered at intervals of up to 16 weeks.The most common adverse reaction is conjunctival hemorrhage.The pharmacology,pharmacokinetics,clinical evaluation,as well as dosage and administration of faricimab are reviewed in this article,aiming to provide reference for clinical rational drug use.